Navicixizumab - Celgene Corporation/OncoMed Pharmaceuticals

Drug Profile

Navicixizumab - Celgene Corporation/OncoMed Pharmaceuticals

Alternative Names: OMP 305B83

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Stem cell modulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 24 Sep 2018 Updated efficacy and adverse events data from a phase Ia trial in Solid tumours released by OncoMed Pharmaceuticals
  • 20 Sep 2018 Celgene decides not to exercise a licensing option of navicixizumab
  • 02 Aug 2018 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top